Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.

Date publication

août 2016

Journal

Liver international : official journal of the International Association for the Study of the Liver

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre

Tous les auteurs :
Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26901163

Résumé

Treatment approaches for hepatocellular carcinoma (HCC) vary across countries, but these differences and their potential impact on outcomes have not been comprehensively assessed. Data from the multinational GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) registry evaluated differences in patient characteristics, practice patterns and outcomes in HCC across geographical regions in patients who received sorafenib.

Référence

Liver Int.. 2016 Aug;36(8):1196-205